Praxis Precision Medicines, Inc. Common Stock
PRAX US74006W1080
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-64% | -88% | -42% | 268% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Mastrocola Lauren CCO |
81.78 USD |
5,188 Sold |
424,318 USD |
14/11/2024 | 14/11/2024 |
Mastrocola Lauren CCO |
81.78 USD |
5,188 Sold |
424,318 USD |
14/11/2024 | 14/11/2024 |
Nemiroff Alex SR OFF |
80.20 USD |
8,239 Sold |
660,827 USD |
14/11/2024 | 14/11/2024 |
Nemiroff Alex SR OFF |
80.20 USD |
8,239 Sold |
660,827 USD |
14/11/2024 | 14/11/2024 |